PMID- 20124511
OWN - NLM
STAT- MEDLINE
DCOM- 20100520
LR  - 20220317
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 115
IP  - 16
DP  - 2010 Apr 22
TI  - High-dose cyclophosphamide as single-agent, short-course prophylaxis of 
      graft-versus-host disease.
PG  - 3224-30
LID - 10.1182/blood-2009-11-251595 [doi]
AB  - Because of its potent immunosuppressive yet stem cell-sparing activity, high-dose 
      cyclophosphamide was tested as sole prophylaxis of graft-versus-host disease 
      (GVHD) after myeloablative allogeneic bone marrow transplantation (alloBMT). We 
      treated 117 patients (median age, 50 years; range, 21-66 years) with advanced 
      hematologic malignancies; 78 had human leukocyte antigen (HLA)-matched related 
      donors and 39 had HLA-matched unrelated donors. All patients received 
      conventional myeloablation with busulfan/cyclophosphamide (BuCy) and T 
      cell-replete bone marrow followed by 50 mg/kg/d of cyclophosphamide on days 3 and 
      4 after transplantation. The incidences of acute grades II through IV and grades 
      III through IV GVHD for all patients were 43% and 10%, respectively. The 
      nonrelapse mortality at day 100 and 2 years after transplantation were 9% and 
      17%, respectively. The actuarial overall survival and event-free survivals at 2 
      years after transplantation were 55% and 39%, respectively, for all patients and 
      63% and 54%, respectively, for patients who underwent transplantation while in 
      remission. With a median follow-up of 26.3 months among surviving patients, the 
      cumulative incidence of chronic GVHD is 10%. These results suggest that high-dose 
      posttransplantation cyclophosphamide is an effective single-agent prophylaxis of 
      acute and chronic GVHD after BuCy conditioning and HLA-matched BMT 
      (clinicaltrials.gov no. NCT00134017).
FAU - Luznik, Leo
AU  - Luznik L
AD  - Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns 
      Hopkins University School of Medicine, Baltimore, MD 21231, USA. luznile@jhmi.edu
FAU - Bolanos-Meade, Javier
AU  - Bolanos-Meade J
FAU - Zahurak, Marianna
AU  - Zahurak M
FAU - Chen, Allen R
AU  - Chen AR
FAU - Smith, B Douglas
AU  - Smith BD
FAU - Brodsky, Robert
AU  - Brodsky R
FAU - Huff, Carol Ann
AU  - Huff CA
FAU - Borrello, Ivan
AU  - Borrello I
FAU - Matsui, William
AU  - Matsui W
FAU - Powell, Jonathan D
AU  - Powell JD
FAU - Kasamon, Yvette
AU  - Kasamon Y
FAU - Goodman, Steven N
AU  - Goodman SN
FAU - Hess, Allan
AU  - Hess A
FAU - Levitsky, Hyam I
AU  - Levitsky HI
FAU - Ambinder, Richard F
AU  - Ambinder RF
FAU - Jones, Richard J
AU  - Jones RJ
FAU - Fuchs, Ephraim J
AU  - Fuchs EJ
LA  - eng
SI  - ClinicalTrials.gov/NCT00134017
GR  - P01 CA015396/CA/NCI NIH HHS/United States
GR  - R01 CA127574/CA/NCI NIH HHS/United States
GR  - R01 CA127574-04/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100202
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Immunosuppressive Agents)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bone Marrow Transplantation/*adverse effects/mortality
MH  - Cyclophosphamide/*administration & dosage
MH  - Disease-Free Survival
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Graft vs Host Disease/*prevention & control
MH  - Hematologic Neoplasms/mortality/*therapy
MH  - Humans
MH  - Immunosuppressive Agents/*administration & dosage
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Transplantation Conditioning/methods
MH  - Transplantation, Homologous
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC2858487
EDAT- 2010/02/04 06:00
MHDA- 2010/05/21 06:00
PMCR- 2011/04/22
CRDT- 2010/02/04 06:00
PHST- 2010/02/04 06:00 [entrez]
PHST- 2010/02/04 06:00 [pubmed]
PHST- 2010/05/21 06:00 [medline]
PHST- 2011/04/22 00:00 [pmc-release]
AID - S0006-4971(20)35120-X [pii]
AID - 2009/251595 [pii]
AID - 10.1182/blood-2009-11-251595 [doi]
PST - ppublish
SO  - Blood. 2010 Apr 22;115(16):3224-30. doi: 10.1182/blood-2009-11-251595. Epub 2010 
      Feb 2.